← All trials
NCT01963442
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2013
- Primary completion
- Oct 1, 2016
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 310
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of VersaillesLead sponsor
- University of VersaillesOverall official - principal investigator
- University of GrenobleOverall official - principal investigator
- University of ParisOverall official - principal investigator
- CH ArgenteuilOverall official - principal investigator
- Rouen Normandy UniversityOverall official - principal investigator
- Centre Hospitalier Intercommunal CreteilOverall official - principal investigator
- Melun HospitalOverall official - principal investigator
- CH Saint DenisOverall official - principal investigator
- University of RennesOverall official - principal investigator
- Assistance Publique - Hôpitaux de ParisOverall official - principal investigator
- University of VersaillesReponsible party - principal investigator
- CH AnnecyOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.